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Abstract
Central-line-associated bloodstream infections (CLABSIs) are responsible for ∼1/3 of all deaths from healthcare-associated
infections in the United States. Of these, multidrug-resistant organisms (MDROs) are responsible for 20% to 67%. However, whether
catheter removal affects clinical outcomes for MDRO CLABSIs has not been studied. Our objective was to determine the relationship
between failure to remove a central venous catheter (CVC) and 30-day all-cause mortality in patients with MDRO CLABSIs. We used
a retrospective cohort from Barnes-Jewish Hospital (1/1/2009–10/1/2015) to study patients with a multidrug-resistant
Staphylococcus aureus, Enterococcus species, Enterobacteriaceae, Acinetobacter species, or Pseudomonas aeruginosa CLABSI.
Risk factors for 30-day mortality, including catheter removal, were assessed for association with 30-day mortality using Cox
proportional hazards models. The CLABSIs were assessed prospectively at the time of occurrence by infection prevention
specialists. A total of 430 patients met inclusion criteria, 173 (40.2%) with Enterococcus, 116 (27.0%) Enterobacteriaceae, 81
(18.8%) S aureus, 44 (10.2%) polymicrobial, 11 (2.6%) P aeruginosa, and 5 (1.2%) Acinetobacter CLABSIs. Removal of a CVC
occurred in 50.2% of patients, of which 4.2% died by 30 days (n=9). For patients whose CVC remained in place, 45.3% died (n=97).
Failure to remove a CVC was strongly associated with 30-day all-cause mortality with a hazard ratio of 13.5 (6.8–26.7), P< .001.
Other risk factors for 30-day mortality included patient comorbidities (cardiovascular disease, congestive heart failure, cirrhosis), and
being in an intensive care unit at the time of MDRO isolation. Failure to remove a CVC was strongly associated with 30-day all-cause
mortality for patients with MDRO CLABSIs in this single center retrospective cohort. This suggests that patients presenting with
MDRO CLABSIs should all undergo CVC removal.
Abbreviations: APACHE = Acute Physiology and Chronic Health Evaluation, CDC =Centers for Disease Control and Prevention,
CLABSIs = Central-line-associated bloodstream infections, CVC = Central venous catheter, HAI = healthcare-associated infection,
IP = infection prevention, IQRs = interquartile ranges, MDROs = multidrug-resistant organisms.
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1. Introduction
Central-line-associated bloodstream infections (CLABSIs) are one
of the most common causes of healthcare-associated infections
(HAIs). There are>20,000CLABSIs each year in the United States
and signiﬁcantly more worldwide.[1,2] In addition, CLABSIs are
responsible for one-third of all deaths from HAIs in the United
States and associated with billions of dollars in excess costs.[3,4]
Guidelines for treatment of CLABSIs have been developed that
recommend central line removal inmany situations,[5] but they did
not speciﬁcally consider the management of multidrug-resistant
organism (MDRO) CLABSIs. At present, guidelines suggest that
for enterococcal and gram-negative bacillus CLABSIs, retaining
the central venous catheter (CVC) is an option (if antibiotic-lock
therapy is used concurrently).[5]
As MDROs are more difﬁcult to treat,[6] source control with
catheter removal would, in theory, be more critical for patients
with MDRO CLABSIs, but this has not yet been studied.
Staphylococcus aureus, Enterobacteriacaeae, Pseudomonas aeru-
ginosa, Enterococcus, and Acinetobacter make up over half of all
CLABSI pathogens and are drug-resistant threats listed by the
Centers for Disease Control and Prevention (CDC).[6–9] MDROs
are responsible for 20% to 67% of all CLABSIs, making it critical
to understand the bestmanagement strategy for these patients.[8,10]
Therefore, it was our goal to determine the relationship between
failure to remove a CVC and 30-day all-causemortality in patients
with MDRO CLABSIs. We utilized multiple deﬁnitions of drug
resistance as outlined by the CDC and European CDC
(Supplemental Table 1).[11–13] Understanding the association
between central-line removal andmortalitywill help guide catheter
removal decisions for patients with MDRO CLABSIs.
2. Materials and methods
2.1. Study location and patient population
This study was conducted at Barnes-Jewish Hospital, a 1250 bed
academic medical center located in St Louis, MO. The study
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period was January 1, 2009 to October 1, 2015. All hospitalized
patients with a positive blood culture for Enterobacteriaceae,
Enterococcus spp, S. aureus, P aeruginosa, or Acinetobacter spp.
were analyzed for eligibility. Organisms were identiﬁed using
culture andMatrix Assisted Laser Desorption-Ionization Time of
Flight Mass Spectrometry with Vitek MS v2.0 software
(bioMerieux, Durham, NC). Antimicrobial susceptibilities for
all pathogens were determined using disc diffusion methodology.
Patients were excluded if they had drug-susceptible pathogens or
died or were discharged within 24hours after the ﬁrst positive
culture was collected. This study was approved by the
Washington University School of Medicine Institutional Review
Board with a waiver of informed consent.
2.2. Study design and data collection
Utilizing a retrospective cohort study design, the ﬁrst hospitali-
zation between January 2009 and October 2015 of all patients
age ≥18 with MDR Enterobacteriaceae, Enterococcus spp, S
aureus, P aeruginosa, or Acinetobacter spp. isolated from blood
culture were identiﬁed. Beginning in 2009, infection prevention
(IP) specialists reviewed all blood cultures to determine if patients
had a CLABSI. Based on the determination of the IP specialists at
the time of the cultures, we excluded all patients who were
determined not to have a CLABSI. All CLABSI determinations
were made based on National Healthcare Safety Network
deﬁnitions in use at the time the culture was drawn.[14] The
primary endpoint was 30-day all-cause mortality. Baseline
characteristics, including age, gender, race, Acute Physiology
and Chronic Health Evaluation (APACHE) II scores (calculated
based on clinical data from the 24hours before and after positive
cultures were obtained), and medical comorbidities (based on
ICD-9-CM diagnosis codes) were obtained. Patients who died
during the index hospitalization or were discharged on hospice
were considered to be expired at the time of hospital discharge.
Over 50% of patients entering hospice care die within 3 weeks[15]
and often cannot receive intravenous antibiotic therapy. In
addition, the majority of patients entering hospice care do not
recover to the point of being discharged alive from hospice
care.[16] Therefore, we considered the expiration date for patients
discharged on hospice to be the date of hospital discharge.
2.3. Deﬁnitions and data sources
Time to death was calculated from the day that a positive culture
qualifying for a MDRO CLABSI was obtained. All data were
obtained from the BJC Healthcare Informatics database,
maintained by the Center for Clinical Excellence, BJC Health-
care. Expiration dates from stays in any BJC facility are included
in the Informatics database. Patients without follow up in the BJC
system and not in the Social Security Death Index (SSDI) were
considered lost to follow-up on their last date of care in a BJC
facility (a total of 18 patients, 4.2% of the cohort).
2.3.1. DeﬁningMDROs.We utilized multiple deﬁnitions of drug
resistance as outlined by the CDC and European CDC
(Supplemental Table 1).[11–13] Any Enterobacteriaceae was
presumed to be an extended-spectrum beta lactamase producer
if ceftriaxone or ceftazidime was intermediate or resistant.
Patients were considered to have a vancomycin intermediate S
aureus infection if S aureus isolated in culture was determined to
have a vancomycin MIC of 4 or 8mg/mL, in accordance with
Clinical & Laboratory Standards Institute recommendations.[17]
2.3.2. Central lines. We included all patients with short-term
and long-term CVCs. Catheter removal dates were conﬁrmed by
retrospective chart review, including chest X-ray visualization
when electronic medical records were insufﬁcient to make a
removal date determination. For patients where the central line
was removed at or in the 24hours before positive culture, lines
were considered to be removed at 0hours.
2.4. Statistical analysis
Comparisonsbetween survivors andnonsurvivorswereperformed
using the Chi-squred or the Fisher exact test for categorical values
and Student t test or Mann–Whitney U test for continuous
variables. Continuous variables were reported as means with
standard deviations or medians and interquartile ranges (IQRs).
Categorical data were expressed as frequencies. Kaplan–Meier
curves were generated to graphically demonstrate the relationship
between catheter removal and30-day all-causemortality,with log-
rank test for signiﬁcance. Multivariate Cox proportional hazards
models were used to determine risk factors for 30-day mortality.
The proportional hazards assumption was checked graphically
using a log-log survival plot. A P value of <.05 was considered
signiﬁcant in all analyses. Factors associated with mortality in
bivariate analysis (P< .10) were entered into a backward stepwise
Cox proportional hazardsmodel to determine hazard ratios (HRs)
for death. In addition, factors associated with CVC removal
(P< .2) were entered into the Cox proportional hazards model for
death. All variables entered into the model were assessed for
collinearity. For patients who underwent CVC removal, we used
Mann–WhitneyU tests to compare time to removal as a risk factor
for death. All analyses were conducted with SPSS version 25
software (IBM, Armonk, NY).
3. Results
A total of 430 patients with MDRO CLABSIs were identiﬁed,
173 (40.2%) with Enterococcus, 116 (27.0%) Enterobacter-
iaceae, 81 (18.8%) S aureus, 44 (10.2%) polymicrobial, 11
(2.6%) P aeruginosa, and 5 (1.2%) Acinetobacter. Among
patients with enterococcal CLABSIs, 90.2% (n=156) were due to
Enterococcus faecium and 9.8% (n=17) due to E. faecalis.
Among patients with Enterobacteriaceae CLABSIs, the majority
were due to Enterobacter cloacae at 46.6% (n=54) and
Escherichia coli 29.3% (n=34). The remaining were due to
Klebsiella aerogenes (n=10), K. pneumoniae (n=6), Citrobacter
freundii (n=5), other Enterobacter species (n=3), and Proteus
mirabilis (n=2). Among patients with polymicrobial MDRO
infections, 15.9% (n=7) were all gram-positive, 11.4% (n=5)
were all gram-negative, and 72.7% (n=32) were mixed gram-
positive/gram-negative infections.
TheCVCremoval occurred in50.2%ofpatients, ofwhich4.2%
died within 30 days (n=9) of culture. Patients who did not have
theirCVC removedhad lowerAPACHE II scores,weremore likely
tohavea bonemarrow transplant or lymphomaorhavebeen in the
intensive care unit (ICU) at the time of the MDRO CLABSI, and
were less likely to have end-stage renal disease or paralysis
(Supplemental Table 2). For patients whose CVC remained in
place, 45.3% (n=97) died within 30 days of culture. Failure to
remove a CVC was signiﬁcantly associated with 30-day all-cause
mortality (Fig. 1). Among patients with gram-positive MDRO
CLABSIs that did not have catheters removed, 30-day mortality
was 54.1%;mortality was 5.0% for those who had their catheters
removed. Analogously, for gram-negative MDRO CLABSIs that
Burnham et al. Medicine (2018) 97:42 Medicine
2
did not have catheters removed, 30-day mortality was 32.9%;
mortality was 1.6% for those who had their catheters removed.
Within 30 days, 8 patients had recurrent MDRO infections, 6/8
with organisms in the same class as the initial infection, 3
Enterobacteriaceae, 1 each of Pseudomonas, Enterococcus, and S
aureus. The remaining 2 patients had different initial and
subsequent MDRO infections.
Among patients who underwent CVC removal, the time to
CVC removal was not signiﬁcantly different between survivors
and nonsurvivors (P= .94). In survivors, the median time to
removal was 4.4 IQR (2.4–8.7) days and 4.8 (2.3–6.9) days in
nonsurvivors.
In bivariate analysis, nonsurvivors were less likely to have their
CVC removed or have MDR Enterobacteriaceae CLABSIs, more
likely to have a bone marrow transplant, cardiovascular disease,
congestive heart failure (CHF), chronic respiratory failure, cirrhosis,
metastatic cancer, be in the ICU at the time of theMDROCLABSI,
or have Enterococcus CLABSIs (Table 1). After adjustment using a
multivariate Cox proportional hazards model, failure to remove
a CVC was strongly associated with 30-day all-cause mortality
with a hazard ratio of 13.5 (6.8–26.7), P< .001. Other risk factors
for 30-daymortality included patient comorbidities (cardiovascular
disease, CHF, cirrhosis), and being in an intensive care unit at the
time of the MDRO CLABSI (see Table 2).
4. Discussion
Infections due to MDROs cause more than 2 million infections
and 23,000deaths/year in the United States,[6] and their incidence
is on the rise globally.[6,18,19] In addition, MDRO infections are
associated with a 2- to 3-fold increase in hospital costs, a >12
days increase in hospital length of stay,[20] 30-day readmission
rates exceeding 30%,[21] and 1-year mortality of 35% to
60%.[22] Therefore, identifying factors that can improve out-
comes for patients with these difﬁcult to treat infections are
critical. In this study, we identify CVC removal as a possible
method to improve outcomes in patients with MDRO CLABSIs.
Among CLABSIs, MDROs account for 20% to 67% of cases,
reinforcing the importance of understanding best management
strategies for these infections.[8,10]
We found that CVC removal was associated with decreased 30-
day all-causemortality for patientswith variousMDROCLABSIs.
Previous studies have shown that failure to remove a CVC is
associated with an increased risk of hematogenous complications
as well as mortality.[23,24] In one study of gram-negative
CLABSIs,[25] there was a strong association between failure to
remove a CVC and mortality. In addition, this study included
patients with MDR gram-negative CLABSIs and found that CVC
removalwas particularly helpful in reducingmortality in this small
sub group. We conﬁrm these ﬁndings in a larger group of MDRO
CLABSI patients and with a broader range of pathogens.
AmongMDRO CLABSI patients that had their CVC removed,
we did not ﬁnd an association between the timing of catheter
removal and mortality. Previous studies have found mixed results
regarding timing of catheter removal and mortality.[25,26] Given
the largeburdenof unremovedCVCs inour study, it seemsprudent
to remove a CVC once a MDRO CLABSI has been identiﬁed as a
ﬁrst step in improving patient outcomes. Future studies with larger
sample sizes can help clarify what role early CVC removal has in
impacting clinical outcomes of MDRO CLABSIs.
Though the Infectious Diseases Society of America (IDSA)
CLABSI guideline updates are in progress, our study adds to the
body of evidence suggesting that for Enterococcus CLABSIs,[24]
catheter removal should be a focus of therapy, as it was not
mandated in previous guidelines.[5]
Our study has several limitations. The retrospective nature of
the study makes it difﬁcult to elucidate possible confounders that
could have biased the outcome measures. It is possible that
patients with short- and long-term CVCs have different mortality
rates when CVCs are not removed after MDRO CLABSI.
Figure 1. Kaplan–Meier curve for time to death with and without central venous catheter (CVC) removal.
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However, it was impossible for us to retrospectively determine
the type of CVC in each patient due to limitations of
documentation in our electronic medical record system. In
addition, the retrospective design of our study makes it
impossible to determine why CVCs were left in place. We
attempted to determine the reasons that CVCs remained in place
for a random sample of 10% of the patients. During this review,
we were unable to ﬁnd any documentation as to why the CVC
was left in place due to one of 3 reasons: CVC was not discussed,
notes were illegible and no assessment was possible, or notes from
the time of catheter removal could not be retrieved.
This was a single-center study and results may not be
generalizable to other centers. Our cohort was predominantly
white, middle-aged males, which may not be generalizable to
other centers. However, patients more likely to need CVCs such
as those receiving stem cell transplants or on dialysis are more
likely to be older, white males, so our results may applicable in
many settings with transplant and dialysis centers.[27,28] The
strength of the association between failure to remove a CVC and
mortality is robust and likely applicable to other tertiary-care
referral centers with similar patient case mixes. Another strength
of our study is the size of the cohort, 430 patients with MDRO
CLABSIs. In previous studies from our institution, we have
shown high rates of drug resistance for various infections,
ranging from 20% to 33%.[29–32]
As MDROs are more difﬁcult to treat,[6] source control with
catheter removal would, in theory, be more critical for patients
with MDRO CLABSIs, but we are limited by a lack of data on
non-MDRO pathogens. Previous work has shown that patients
with gram-negative MDRO CLABSIs fare worse when their
catheters are not removed.[25] Therefore, we felt it was more
useful to include different types of MDROs rather than
comparing to patients with non-MDRO infections. In addition,
there were differences between patients that had their catheter
removed and those that did not. We tried to account for this by
including these factors in our multivariate Cox-proportional
hazards model.
Another limitation of our study is the unavailability of
antibiotic treatment data. Inappropriate antimicrobial therapy is
a known risk factor for mortality in patients with bloodstream
infections[33] and this could affect the hazards ratios for death
that we calculated in our Cox proportional hazards model.
However, the strength of association between failure to remove a
CVC and mortality is strong enough that it is unlikely that
addition of antibiotic treatment data would negate this risk
factor. Future studies should incorporate antibiotic treatment
data into their multivariate models to deﬁnitively address this
limitation.
In conclusion, failure to remove a CVC for patients with
MDRO CLABSIs is associated with increased 30-day all-cause
mortality. Comorbidities and requiring ICU care also were risk
factors for mortality. By analyzing outcomes after MDRO
CLABSI, we hope to encourage all providers to remove CVCs
whenever a MDRO CLABSI is identiﬁed.
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CVC not removed %, (n) 36.1 (117) 91.5 (9) <.001
MDRO pathogen .028
Enterobacteriaceae 29.6 (96) 18.9 (20)
Enterococcus 35.8 (116) 53.8 (57)
Staphylococcus aureus 20.4 (66) 14.2 (15)
Acinetobacter 0.9 (3) 1.9 (2)
Pseudomonas aeruginosa 2.5 (8) 2.8 (3)
Polymicrobial 10.8 (35) 8.5 (9)
Female 42.3 (137) 40.6 (43) .76
Nonwhite 26.5 (86) 28.3 (30) .72
Age, median (IQR) 58.3 (48.0–64.6) 59.7 (49.2–67.5) .15
APACHE-II score, median (IQR) 10 (7–13) 10 (7–14) .16
Comorbidities
BMT 12.7 (41) 20.8 (22) .041
Cardiovascular disease 58.3 (189) 81.1 (86) <.001
CHF 17.3 (56) 32.1 (34) .001
Chronic respiratory failure 21.6 (70) 34.0 (36) .010
Cirrhosis 8.6 (28) 16.0 (17) .031
CKD 20.4 (66) 24.5 (26) .37
Diabetes 31.8 (103) 36.8 (39) .34
ESRD 10.5 (34) 10.4 (11) .97
Lymphoma 17.9 (58) 17.0 (18) .83
Solid organ malignancy 18.2 (59) 22.6 (24) .32
SOT 4.6 (15) 4.7 (5) .97
Paralysis 6.5 (21) 2.8 (3) .22
HIV/AIDS 0.3 (1) 1.9 (2) .15
Metastatic cancer 2.8 (9) 8.5 (9) .011
Collagen vascular disease 2.2 (7) 0 .20
PPM 1.5 (5) 3.8 (4) .23
ICD 1.5 (5) 4.7 (5) .072
In ICU at time of positive MDRO culture 38.6 (125) 64.2 (68) <.001
AIDS= acquired immunodeﬁciency syndrome, APACHE=Acute Physiology and Chronic Health
Evaluation, BMT=Bone marrow transplant, CHF= congestive heart failure, CKD= chronic kidney
disease, CVC= central venous catheter, ESRD=End-stage renal disease, HIV=human immuno-
deﬁciency virus, ICD= implanted cardioverter deﬁbrillator, ICU= intensive care unit, IQR= interquartile
range, MDRO=multidrug-resistant organism, PPM=permanent pacemaker, SOT= solid organ
transplant.
Table 2
Risk factors for 30-day all-cause mortality from backward




(95% CI) for 30-day
all-cause mortality P-value
CVC not removed 13.5 (6.79–26.7) <.001
Comorbidities
Cardiovascular disease 2.25 (1.35–3.76) .002
CHF 1.59 (1.03–2.46) .035
Cirrhosis 2.28 (1.34–3.87) .002
In ICU on date of MDRO CLABSI culture 1.99 (1.33–2.97) .001
Variables included in the initial model that were ultimately not retained through backward stepwise
regression include MDRO pathogen type, metastatic cancer, presence of an automated implantable
cardioverter-deﬁbrillator, receipt of a bone marrow transplant, chronic respiratory failure, race, end-
stage renal disease, lymphoma, paralysis, and APACHE II score.
CHF=congestive heart failure, CI= conﬁdence interval, CVC= central venous catheter, HR=hazard
ratio, ICU= intensive care unit, MDRO=multidrug-resistant organism.
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